Johnson & Johnson Vision Receives FDA Clearance for Catalys cOS 6.0 Software for Astigmatism Management

Source: Johnson & Johnson Vision

The FDA has granted 510(k) clearance for new software for the Catalys Precision Laser System that aims to simplify astigmatism management workflow and increase operational efficiency.

The Catalys cOS 6.0 software with advanced astigmatism management is a collaboration with Cassini Technologies B.V. The advancements build on the laser cataract surgery essentials of the Catalys system, with features such as advanced visualization that provide full-volume, 3D, high-resolution, and streaming Optical Coherence Tomography imaging, as well as reliable, accurate laser incisions and premium patient experience, according to a company news release.

“Accuracy and precision in astigmatic procedures are critical to good outcomes,” Douglas Koch, MD, said in the news release. “Catalys cOS 6.0 with advanced astigmatism management not only provides more accurate surgical alignment and automatic cyclorotation compensation that is three times better than manual markings, the workflow will make the entire process easier and faster for me.”

Catalys cOS 6.0 with advanced astigmatism management streamlines workflow, speeds up the surgical process and improves accuracy by:

  • Minimizing data entry verification and manual transcription errors through direct input of preoperative keratometry and steep axis values data
  • Reducing time spent on calculations, by including calculation of arcuate incision parameters using built-in nomogram and automatic input of arcuate incision parameters into the treatment planning screen
  • Reduces need for intraoperative aberrometry for toric IOL alignment with radial laser marks placed within a mean accuracy of 0.6° provide 5.5X greater precision compared to manual marking of the cornea with an ink pen (mean accuracy 3.3°)
  • Addition of iris registration for automatic cyclorotation compensation, through collaboration with Cassini Technologies

Catalys cOS 6.0 will be commercially available in Q4 2020.


Related Content